ENOV vs TMCI
ENOV: A medical technology company providing a comprehensive continuum of orthopedic care, from injury prevention and rehabilitation products to surgical reconstructive implants. TMCI: Treace is a focused orthopedic medical device company specializing in innovative 3D bunion correction and foot surgery systems for hospitals and surgical centers.
Side-by-side fundamentals
| Metric | ENOV | TMCI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $26.55 | $3.97 | |
| Market cap as of 2026-07-23 | $1.5B | $258M | |
| PEG as of 2026-07-23 | -0.04 | -0.35 | TMCI lower |
| Net margin as of 2026-07-23 | -49.9% | -29.4% | TMCI higher |
| Gross margin as of 2026-07-23 | +60.4% | +79.7% | TMCI higher |
| Operating margin as of 2026-07-23 | -47.1% | -28.2% | TMCI higher |
| ROE as of 2026-07-23 | -60.1% | -69.5% | ENOV higher |
| ROA as of 2026-07-23 | -26.6% | -31.4% | ENOV higher |
| Debt / equity as of 2026-07-23 | 0.90 | 0.72 | TMCI lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.0% | -1.7% | ENOV higher |
| Revenue CAGR (3y) SEC XBRL | +12.9% | +14.5% | TMCI higher |
| Beta as of 2026-07-23 | 1.47 | 1.40 | |
| 1-year return as of 2026-07-22 close | +3.0% | -26.0% | ENOV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.